Cambrex Corporation (NYSE:CBM) will release its earnings data before the market opens on Monday, July 31st. Analysts expect Cambrex Corporation to post earnings of $0.76 per share for the quarter. Cambrex Corporation has set its FY17 guidance at $2.94-3.06 EPS.
Cambrex Corporation (NYSE:CBM) last released its earnings results on Thursday, May 4th. The biotechnology company reported $0.68 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.51 by $0.17. Cambrex Corporation had a return on equity of 24.92% and a net margin of 17.36%. The firm had revenue of $105.01 million during the quarter, compared to analysts’ expectations of $99.05 million. During the same period in the previous year, the firm posted $0.50 EPS. Cambrex Corporation’s revenue for the quarter was up 10.9% on a year-over-year basis. On average, analysts expect Cambrex Corporation to post $3.02 EPS for the current fiscal year and $3.24 EPS for the next fiscal year.
Cambrex Corporation (NYSE:CBM) opened at 60.10 on Friday. The company’s 50-day moving average price is $58.78 and its 200 day moving average price is $55.30. Cambrex Corporation has a 1-year low of $38.30 and a 1-year high of $62.95. The firm has a market capitalization of $1.96 billion, a PE ratio of 22.88 and a beta of 2.28.
CBM has been the subject of several recent research reports. Zacks Investment Research downgraded Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. BidaskClub upgraded Cambrex Corporation from a “sell” rating to a “hold” rating in a report on Saturday, June 10th. Finally, ValuEngine downgraded Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Cambrex Corporation has an average rating of “Buy” and an average price target of $64.00.
ILLEGAL ACTIVITY WARNING: “Cambrex Corporation (NYSE:CBM) to Release Quarterly Earnings on Monday” was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/07/29/cambrex-corporation-nysecbm-to-release-quarterly-earnings-on-monday.html.
In related news, Director Leon J. Hendrix, Jr. sold 20,656 shares of the stock in a transaction on Tuesday, June 6th. The stock was sold at an average price of $55.95, for a total value of $1,155,703.20. Following the completion of the sale, the director now directly owns 74,662 shares in the company, valued at approximately $4,177,338.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Steven M. Klosk sold 12,000 shares of the stock in a transaction on Monday, May 1st. The shares were sold at an average price of $58.20, for a total value of $698,400.00. Following the completion of the sale, the chief executive officer now owns 95,328 shares of the company’s stock, valued at $5,548,089.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 70,656 shares of company stock valued at $4,026,143. 2.48% of the stock is owned by insiders.
About Cambrex Corporation
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.